JP2024542096A - 新規タンパク質 - Google Patents
新規タンパク質 Download PDFInfo
- Publication number
- JP2024542096A JP2024542096A JP2024526578A JP2024526578A JP2024542096A JP 2024542096 A JP2024542096 A JP 2024542096A JP 2024526578 A JP2024526578 A JP 2024526578A JP 2024526578 A JP2024526578 A JP 2024526578A JP 2024542096 A JP2024542096 A JP 2024542096A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- fusion protein
- polypeptide
- disease
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2115803.5 | 2021-11-03 | ||
| GBGB2115803.5A GB202115803D0 (en) | 2021-11-03 | 2021-11-03 | Novel proteins |
| PCT/GB2022/052764 WO2023079278A1 (en) | 2021-11-03 | 2022-11-03 | Novel proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542096A true JP2024542096A (ja) | 2024-11-13 |
| JP2024542096A5 JP2024542096A5 (cg-RX-API-DMAC7.html) | 2025-10-30 |
Family
ID=78828504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526578A Pending JP2024542096A (ja) | 2021-11-03 | 2022-11-03 | 新規タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250026805A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4426719A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024542096A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099427A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118369334A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022381844A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3236737A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202115803D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312470A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023079278A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2626300A (en) * | 2022-12-08 | 2024-07-24 | Ducentis Biotherapeutics Ltd | Mutated CD200 proteins and methods of use therof |
| GB202306711D0 (en) * | 2023-05-05 | 2023-06-21 | Ducentis Biotherapeutics Ltd | Novel proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| EP1171154A2 (en) | 1999-04-13 | 2002-01-16 | Schering Corporation | Uses of mammalian ox2 protein and related reagents |
| WO2008089022A2 (en) | 2007-01-11 | 2008-07-24 | Boehringer Ingelheim International Gmbh | Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts |
| GB201608197D0 (en) * | 2016-05-10 | 2016-06-22 | Ducentis Biotherapeutics Ltd | Novel proteins |
-
2021
- 2021-11-03 GB GBGB2115803.5A patent/GB202115803D0/en not_active Ceased
-
2022
- 2022-11-03 CA CA3236737A patent/CA3236737A1/en active Pending
- 2022-11-03 JP JP2024526578A patent/JP2024542096A/ja active Pending
- 2022-11-03 EP EP22802232.3A patent/EP4426719A1/en active Pending
- 2022-11-03 US US18/707,321 patent/US20250026805A1/en active Pending
- 2022-11-03 IL IL312470A patent/IL312470A/en unknown
- 2022-11-03 AU AU2022381844A patent/AU2022381844A1/en active Pending
- 2022-11-03 KR KR1020247018665A patent/KR20240099427A/ko active Pending
- 2022-11-03 WO PCT/GB2022/052764 patent/WO2023079278A1/en not_active Ceased
- 2022-11-03 CN CN202280081085.3A patent/CN118369334A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240099427A (ko) | 2024-06-28 |
| WO2023079278A1 (en) | 2023-05-11 |
| IL312470A (en) | 2024-06-01 |
| EP4426719A1 (en) | 2024-09-11 |
| CA3236737A1 (en) | 2023-05-11 |
| GB202115803D0 (en) | 2021-12-15 |
| CN118369334A (zh) | 2024-07-19 |
| US20250026805A1 (en) | 2025-01-23 |
| AU2022381844A1 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017264825B2 (en) | CD200 mutant and its uses | |
| JP2019531705A (ja) | 操作されたポリペプチドおよびその使用 | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| KR20160130463A (ko) | 다량체 Fc 단백질 | |
| JP7097293B2 (ja) | ヒトFc受容体に結合する融合タンパク質 | |
| US20250026805A1 (en) | Novel proteins | |
| JP2022514187A (ja) | IVIGの代替のための多量体ハイブリッドFc蛋白質 | |
| JP2025515191A (ja) | 新規cd200融合タンパク質 | |
| JP2024546129A (ja) | アルファ-l-イズロニダーゼ酵素を含む融合タンパク質及びその方法 | |
| JP2026516066A (ja) | Cd200融合タンパク質 | |
| US20260116951A1 (en) | Novel cd200 fusion proteins | |
| US20240392035A1 (en) | Engineered anti-her2 bispecific proteins | |
| TW202519543A (zh) | TNF-α變體融合分子 | |
| EA042608B1 (ru) | Мутант cd200 и его применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251020 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251020 |